Developing Neuronal KCNQ Channel Modulators for Mood Disorders
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Retigabine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.
- 29 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
- 08 Feb 2017 New trial record